Participated · Series B · Dec 2025

Sanegene Bio is a biotechnology firm focused on creating RNA interference (RNAi) medicines that target metabolic, cardiovascular, and autoimmune disorders. Its proprietary delivery platform is aimed at improving the clinical utility of RNA-based therapeutics, an area that is experiencing heightened global momentum. The company plans to use its latest capital infusion to advance multiple RNAi programs into registration studies, signaling a move toward late-stage clinical development. Management also intends to broaden the pipeline into additional disease areas within its core therapeutic focus. Although specific revenue or patient enrollment figures were not disclosed, the sizable financing underscores investor confidence in Sanegene Bio’s approach and delivery technology. With substantial strategic backing from industry leaders such as Eli Lilly and repeat participation from prior investors, the company is positioned to accelerate development and expand partnership opportunities.

Participated · Series A · Jul 2024

LTZ Therapeutics is advancing a Universal Myeloid Cell Engager (U-MCE™) platform designed to engage and activate monocytes and macrophages to enhance phagocytosis across oncology and autoimmune indications. Its lead asset, LTZ-301, is a bispecific myeloid engager that redirects monocytes and macrophages to deplete CD79b+ B-cells and is actively enrolling patients with relapsed/refractory non-Hodgkin lymphoma in a Phase 1 study; preclinical data showed potent pharmacology and a favorable safety profile. The company is preparing an IND and plans Phase 1 initiation for its second asset, LTZ-232. LTZ has raised approximately $130 million since its founding in 2022 and will use the recent $38 million financing to accelerate clinical development across its pipeline. The company maintains operations in Redwood City, California and Shenzhen, China, and recently added Erin Lavelle to its board to guide strategic operations.

Participated · Series B · Aug 2022

Sironax is a Beijing-based clinical-stage biotechnology company dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Its pipeline comprises multiple programs focused on key mechanisms including regulated cell death, neuroprotective pathways and neuroinflammation, with lead efforts around RIPK1 inhibitors. The company is conducting early clinical studies with SIR0365 and SIR2446 while advancing additional preclinical research. Sironax plans to use recent financing to support ongoing clinical development of its RIPK1 portfolio and to expand its R&D footprint and pipeline of potential best- and first-in-class candidates. The company closed a $200M Series B led by Gaorong Capital and Yunfeng Capital, with participation from a broad group of existing and new investors. Led by CEO Aaron Ren and founded in 2017, Sironax is positioning to progress its clinical programs targeting age-related degeneration.

Led · Series A · Jun 2022

环码生物 is a biopharmaceutical company focused on developing nucleic acid drugs based on a unique circular RNA technology platform. The company says it possesses globally leading circular RNA design, optimization, preparation technologies and related patents, and was founded by scientists with long experience in RNA research. Scientific founder Wang Zefeng’s team first reported in 2014 that circular RNAs can be translated in human cells, opening applications of circular RNA as a new mRNA therapy. The team includes domestic and international senior biopharma professionals supporting pipeline R&D, process scale-up, quality control and IP strategy. The company plans to use new funds to完善 the circular RNA platform, advance its pipeline, build a Shanghai R&D center and continue recruiting global talent. Management emphasizes circular RNA advantages versus linear mRNA in stability, expression and immunogenicity and intends to push circular RNA therapeutics toward market.